Followers | 4054 |
Posts | 152184 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Thursday, December 26, 2013 4:42:40 PM
(b) Resignation of Director
On December 23, 2013, Michael Bigham tendered his resignation from the board of directors of Supernus Pharmaceuticals, Inc. (the “Company”), effective immediately. Mr. Bigham was the designee of Abingworth Bioventures IV LP and its affiliates (“Abingworth”), an original investor in the Company. His resignation was consistent with Abingworth’s general practice of limiting the time its representatives spend on a portfolio company’s board of directors after it becomes a public company. The Company is presently searching for a replacement to fill the remainder of Mr. Bigham’s term, which expires at the next annual meeting of stockholders in 2014. A copy of the press release regarding the resignation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Mr. Bigham was a member of the Company’s Compensation Committee and Governance and Nominating Committee. John M. Siebert, Ph.D. will fill the vacancy on the Company’s Compensation Committee and M. James Barrett, Ph.D. will fill the vacancy on the Company’s Governance and Nominating Committee.
Item 8.01 Other Events.
On December 23, 2013, Supernus issued a press release announcing that the Food and Drug Administration approved Orenitram™ (treprostinil), Extended Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity. Supernus developed the extended release formulation of Orenitram™ under a Development and License Agreement with United Therapeutics Corporation (NASDAQ: UTHR). The product uses EnSoTrol, Supernus’ novel osmotic technology platform. A copy of the press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following document is furnished as an Exhibit pursuant to Item 5.02 hereof:
Exhibit 99.1 — Press Release Dated December 24, 2013 of the Company providing details regarding the resignation of Michael Bigham from the Company’s board of directors.
Exhibit 99.2 — Press Release Dated December 23, 2013.
Recent SUPN News
- Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree • GlobeNewswire Inc. • 09/24/2024 11:30:33 AM
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit • GlobeNewswire Inc. • 09/19/2024 08:30:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:00:12 PM
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 08:15:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 09:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 09:00:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 11:03:01 AM
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA • GlobeNewswire Inc. • 08/19/2024 11:00:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 09:00:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:18:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:16:00 PM
- Supernus Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/06/2024 08:06:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/02/2024 08:16:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:58:35 PM
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device • GlobeNewswire Inc. • 08/01/2024 08:30:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:19:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/31/2024 08:41:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 08:02:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/29/2024 08:08:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 08:48:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:20:54 PM
- Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 • GlobeNewswire Inc. • 07/23/2024 08:13:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 08:24:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/19/2024 08:28:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:18:19 PM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM